Source: Pharmacogenomics. Unidades: EERP, FMRP
Subjects: FÁRMACOS (SISTEMA CARDIOVASCULAR), CITOCINAS, ÓXIDO NÍTRICO, POLIMORFISMO, PRÉ-ECLÂMPSIA
ABNT
PEREIRA, Daniela A. et al. NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia. Pharmacogenomics, v. 22, n. 8, p. 451-464, 2021Tradução . . Disponível em: https://doi.org/10.2217/pgs-2021-0006. Acesso em: 21 ago. 2024.APA
Pereira, D. A., Sandrim, V. C., Palei, A. C., Amaral, L. M., Belo, V. A., Lacchini, R., et al. (2021). NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia. Pharmacogenomics, 22( 8), 451-464. doi:10.2217/pgs-2021-0006NLM
Pereira DA, Sandrim VC, Palei AC, Amaral LM, Belo VA, Lacchini R, Cavalli R de C, Tanus-Santos JE, Luizon MR. NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia [Internet]. Pharmacogenomics. 2021 ; 22( 8): 451-464.[citado 2024 ago. 21 ] Available from: https://doi.org/10.2217/pgs-2021-0006Vancouver
Pereira DA, Sandrim VC, Palei AC, Amaral LM, Belo VA, Lacchini R, Cavalli R de C, Tanus-Santos JE, Luizon MR. NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia [Internet]. Pharmacogenomics. 2021 ; 22( 8): 451-464.[citado 2024 ago. 21 ] Available from: https://doi.org/10.2217/pgs-2021-0006